Drew Ranieri
Stock Analyst at Morgan Stanley
(1.51)
# 2,505
Out of 4,479 analysts
141
Total ratings
44.59%
Success rate
-16.37%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMCI Treace Medical Concepts | Downgrades: Equal-Weight | $15 → $5.5 | $6.63 | -17.04% | 10 | May 8, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $26 → $25 | $13.00 | +92.31% | 13 | May 7, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $37 → $24 | $29.19 | -17.78% | 9 | May 7, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $30 | $18.00 | +66.67% | 15 | Apr 22, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9 → $13 | $7.23 | +79.81% | 11 | Mar 6, 2024 | |
| SYK Stryker | Maintains: Equal-Weight | $300 → $320 | $334.30 | -4.28% | 6 | Dec 4, 2023 | |
| OM Outset Medical | Maintains: Equal-Weight | $5 → $5.5 | $3.77 | +45.89% | 10 | Dec 4, 2023 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $3 → $3.5 | $2.66 | +31.58% | 3 | Nov 14, 2023 | |
| GMED Globus Medical | Maintains: Equal-Weight | $60 → $53 | $68.05 | -22.12% | 9 | Nov 14, 2023 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $23 → $17 | $9.90 | +71.72% | 7 | Nov 14, 2023 | |
| NVST Envista Holdings | Maintains: Overweight | $42 → $38 | $16.34 | +132.56% | 9 | Nov 2, 2023 | |
| HAE Haemonetics | Maintains: Equal-Weight | $88 → $96 | $83.06 | +15.58% | 9 | May 12, 2023 | |
| AVNS Avanos Medical | Maintains: Underweight | $28 → $26 | $19.50 | +33.33% | 8 | May 4, 2023 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $290 → $295 | $229.24 | +28.69% | 2 | Feb 3, 2023 | |
| TFX Teleflex | Maintains: Equal-Weight | $236 → $280 | $211.25 | +32.54% | 5 | Jan 6, 2023 | |
| BVS Bioventus | Maintains: Overweight | $11 → $5 | $5.78 | -13.49% | 6 | Nov 10, 2022 | |
| BAX Baxter International | Maintains: Overweight | $72 → $70 | $32.85 | +113.09% | 4 | Oct 11, 2022 | |
| ISRG Intuitive Surgical | Maintains: Equal-Weight | $325 → $300 | $438.81 | -31.63% | 5 | Apr 25, 2022 |
Treace Medical Concepts
May 8, 2024
Downgrades: Equal-Weight
Price Target: $15 → $5.5
Current: $6.63
Upside: -17.04%
SI-BONE
May 7, 2024
Maintains: Overweight
Price Target: $26 → $25
Current: $13.00
Upside: +92.31%
Integra LifeSciences Holdings
May 7, 2024
Maintains: Underweight
Price Target: $37 → $24
Current: $29.19
Upside: -17.78%
Stevanato Group
Apr 22, 2024
Maintains: Equal-Weight
Price Target: $30
Current: $18.00
Upside: +66.67%
NeuroPace
Mar 6, 2024
Maintains: Equal-Weight
Price Target: $9 → $13
Current: $7.23
Upside: +79.81%
Stryker
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $300 → $320
Current: $334.30
Upside: -4.28%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $5 → $5.5
Current: $3.77
Upside: +45.89%
Organogenesis Holdings
Nov 14, 2023
Maintains: Equal-Weight
Price Target: $3 → $3.5
Current: $2.66
Upside: +31.58%
Globus Medical
Nov 14, 2023
Maintains: Equal-Weight
Price Target: $60 → $53
Current: $68.05
Upside: -22.12%
Alphatec Holdings
Nov 14, 2023
Maintains: Overweight
Price Target: $23 → $17
Current: $9.90
Upside: +71.72%
Envista Holdings
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $16.34
Upside: +132.56%
Haemonetics
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $83.06
Upside: +15.58%
Avanos Medical
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $19.50
Upside: +33.33%
Becton, Dickinson and Company
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $229.24
Upside: +28.69%
Teleflex
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $211.25
Upside: +32.54%
Bioventus
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $5.78
Upside: -13.49%
Baxter International
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $32.85
Upside: +113.09%
Intuitive Surgical
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $438.81
Upside: -31.63%